Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.

@article{Fillon2018ImmuneCI,
  title={Immune checkpoint inhibitors are superior to docetaxel as second-line therapy for patients with non-small cell lung carcinoma.},
  author={Mike Fillon},
  journal={CA: a cancer journal for clinicians},
  year={2018},
  volume={68 3},
  pages={178-179}
}